Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Novocure

Insulet

High-growth medical-device companies are having a good day.

Why Novocure, Insulet, and Dexcom Are Rising Today

Dexcom's Stock Has Taken A Huge Hit - It Could Be Time To Be Greedy

DexCom's stock can't escape the immense gravity of the market-wide sell-off today.

Why DexCom Stock Is Getting Trounced Today

DexCom (DXCM) reported earnings 30 days ago. What's next for the stock?

DexCom (DXCM) Down 3.3% Since Last Earnings Report: Can It Rebound?

Biogen

Eli Lilly

Masimo

Vertex Pharmaceuticals

In the coronavirus bear market, all stocks are under quarantine. But keep health care stocks Vertex, Biogen, Dexcom, Eli Lilly, Masimo under observation.

Coronavirus Bear Market: All Stocks Are Under Quarantine, But Keep Vertex, Biogen, Dexcom, Eli Lilly, Masimo Under Observation

In the latest trading session, DexCom (DXCM) closed at $247.64, marking a -1.89% move from the previous day.

DexCom (DXCM) Stock Moves -1.89%: What You Should Know

Gilead Sciences

Regeneron Pharmaceuticals

Can these winners in a losing market keep their momentum going?

3 Profitable Healthcare Stocks That Are Trouncing the Market During the Coronavirus Correction

Shares of the medical device maker bucked the coronavirus-driven market sell-off.

Why Diabetes Stock Dexcom Jumped 14.6% in February While the Market Dropped

Datadog

Domino's Pizza

TAL Education Group

Zoom Video

In the coronavirus stock market correction, stay engaged. Dexcom, Zoom Video, Domino's Pizza, Datadog and TAL Education are watch list-worthy.

Dexcom, Domino's, Zoom Video, Datadog, TAL Education Show Strength In Coronavirus Stock Market Correction

Clorox

Netflix

Patterson Companies

Teladoc

Virtu Financial

When the Dow Jones industrial average has seen a drop of close to 3,000 points in less than a week, and with the new U.S.

8 Large-Cap Anti-Coronavirus Stock Winners During This Stock Market Sell-Off

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Dexcom (DXCM).

Is Dexcom (DXCM) a Great Growth Stock?

This agreement is a major step forward in Insulet's (PODD) commitment toward bolstering its automated insulin delivery system and providing better clinical outcomes for diabetes patients.

Insulet Partners With Dexcom for Automated Insulin Delivery

Tandem Diabetes Care

According to The American Diabetes Association, every $1 in $7 spent in healthcare is spent on diabetes or its complications. We look at three companies well-positioned to capture this market.

3 Great Diabetes-Focused Stocks

Abbott Labs

Insulet Corp. (NASDAQ:PODD) hit its 52-week high on Feb. 19 after announcing formation of two partnerships that further strengthens its leading role in the market for continuous glucose monitoring.

Insulet  Partners With Abbott and Dexcom on Diabetes

Insulet Partners With Abbott and DexCom On Diabetes

The worst performer among these stocks has soared more than 70% over the last 12 months.

Want to Get Rich Investing in Healthcare? Check Out These Diabetes Stocks

DexCom (DXCM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Increased Earnings Estimates Seen for DexCom (DXCM): Can It Move Higher?

DexCom (DXCM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why DexCom (DXCM) Stock Might be a Great Pick

Insulet's wearable insulin pumps will be integrated with blood glucose monitors from both companies.

Insulet Announces Agreements With Abbott and DexCom

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DexCom (DXCM) Hits 52-Week High, Can the Run Continue?

As of late, it has definitely been a great time to be an investor in DexCom.

Will DexCom Continue to Surge Higher?

Shares have soared more than 400% in just two years.

Is DexCom's Stock a Buy?

Investors loved the medical device maker's great Q4 results.

Why DexCom Shares Are Flying Higher Today

DexCom's (DXCM) fourth-quarter earnings benefit from higher revenues and solid performing Sensor and Transmitter segments.

DexCom (DXCM) Q4 Earnings and Revenues Surpass Estimates

The medical-device maker delivered good news across the board in the fourth quarter.

News for DexCom Stock (DXCM)